Breaking news on life science and diagnostics business, policy, and funding
HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The firm said that its new hematology-based cellular biomarker test has the potential to advance clinicians’ approach to sepsis triage and diagnosis.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.